PF 4856883

Drug Profile

PF 4856883

Alternative Names: CovX 096; CVX-096; PF-04856883; PF-4856883

Latest Information Update: 10 May 2013

Price : $50

At a glance

  • Originator CovX
  • Developer Pfizer
  • Class Antibodies; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 09 May 2013 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (SC)
  • 17 Jan 2013 Pfizer completes a phase I trial in Healthy volunteers in USA (NCT01637285)
  • 06 Jul 2012 Pfizer plans a phase I trial in Healthy volunteers in USA (NCT01637285)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top